Chembio Diagnostics (CEMI +5.4%) trades up after saying it's commenced Clinical Laboratory Improvement Amendments waiver studies for its DPP HIV 1/2 Assay. The studies are required by the FDA to establish the quality standards for laboratory testing, which ensures the accuracy, reliability and timeliness of patient tests results regardless of where the tests are performed.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs